Clinical Trials Logo

Filter by:
NCT ID: NCT06442527 Not yet recruiting - Clinical trials for Obsessive-Compulsive Disorder

Using Virtual Reality Before Transcranial Magnetic Stimulation for the Treatment of OCD

VR-TMS
Start date: July 2024
Phase: N/A
Study type: Interventional

This study will focus on the use of Virtual Reality (VR) technology in patients receiving treatment using Transcranial Magnetic Stimulation (TMS) for Obsessive-Compulsive Disorder (OCD)

NCT ID: NCT06442514 Not yet recruiting - Pain Clinical Trials

Pain and Smoking Study - Interactive Voice Response

PASS-IVR
Start date: December 1, 2024
Phase: N/A
Study type: Interventional

PASS2 aims to expand upon the recently completed study (PASS intervention), which tested the telephone delivery of a cognitive behavioral intervention (CBI). This study will use Interactive Voice Response (IVR) to optimize the intervention's effectiveness for smoking cessation among Veteran smokers with chronic pain.

NCT ID: NCT06442488 Recruiting - Clinical trials for Respiratory Insufficiency

Wearable Wireless Respiratory Monitoring System That Detects and Predicts Opioid Induced Respiratory Depression

Start date: May 1, 2024
Phase:
Study type: Observational

An observational study will be conducted in approximately 14 participants to evaluate the ability of a wearable, wireless acoustic Respiratory Monitoring System (RMS) to accurately measure a participant's respiratory rate, tidal volume, minute ventilation, and duration of apnea in a noisy environment. Sensor accuracy will be measured with adaptive filtering and active noise cancellation turned on versus turned off.

NCT ID: NCT06442475 Not yet recruiting - Clinical trials for Grade 3a Follicular Lymphoma

Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma

Start date: September 1, 2024
Phase: Phase 2
Study type: Interventional

This phase II trial tests the safety, side effects and effectiveness of mosunetuzumab in treating patients with slow growing (indolent) B-cell lymphoma. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT06442397 Not yet recruiting - Survivorship Clinical Trials

Anti-Inflammatory Lifestyle Intervention for Emerging Adult Cancer Survivors

Start date: June 15, 2024
Phase: N/A
Study type: Interventional

To test the feasibility and acceptability of AILI and associated research procedures among emerging adult cancer survivors (EACS) age 18-29.

NCT ID: NCT06442358 Recruiting - Perinatal Care Clinical Trials

Self Biophysical Profile Using a Home Ultrasound Device Proof of Concept

Start date: April 10, 2024
Phase: N/A
Study type: Interventional

The objective of this study is to assess if patients presenting for antenatal testing can complete a Bio Physical Score (BPP) with a home-use ultrasound with remote clinician guidance.

NCT ID: NCT06442306 Completed - Chronic Pain Clinical Trials

Evaluation of Pain Neuroscience Education for Patients Who Experience Chronic Pain With Concurrent Opioid Dependence

Start date: January 3, 2020
Phase: N/A
Study type: Interventional

Chronic musculoskeletal pain (CMP) is estimated to affect over 100 million adults and is targeted as an instigator of opioid dependence (OpD). Opioid medications are often the first response for patients suffering with CMP; yet over 10 million people admit to misusing opioids annually. With the opioid epidemic, the healthcare system now has a population of patients who experience CMP with concurrent OpD (CMP/OpD). This persistent problem can create a perfect storm of kinesiophobia, reduced self-efficacy, and physical dysfunction. A critical component to chronic pain management is understanding how patients view their pain experience. Education may be one key that unlocks the door to functional improvement, but traditional physical therapy (PT) education utilizes anatomical models that focus on tissue damage and peripheral sources of pain. Researchers have explored educating people about pain via Pain Neuroscience Education (PNE), a cognitive-based intervention that facilitates understanding of the biological processes underpinning the pain state. PNE may facilitate understanding pain experiences that are normal and expected, with the intent to reduce fear and increase pain self-efficacy. As yet, utilization of PNE has not been researched in patients with CMP/OpD. Therefore, authors hypothesize that the introduction of an adapted PNE (a-PNE) curriculum, as a single intervention, may facilitate positive changes in kinesiophobia, pain self-efficacy, and knowledge of the neurophysiology of pain for patients with CMP/OpD.

NCT ID: NCT06442293 Not yet recruiting - Safety Issues Clinical Trials

Safety and Tolerability of 2 Dietary Supplement Beverages Designed to Maintain Healthy Blood Pressure.

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

This study is designed to evaluate the safety and tolerability of two distinct dietary supplement beverage formulations designed to maintain normal blood pressure. In this study, safety and tolerability will be assessed among otherwise healthy, normotensive individuals.

NCT ID: NCT06442098 Recruiting - Clinical trials for Reading Disorder, Developmental

Camp SMART Speech to Print Summer Literacy Camp

Start date: June 11, 2024
Phase: N/A
Study type: Interventional

This project aims to explore the feasibility and efficacy of a 6-week, intensive summer literacy intervention provided to children in 1st-3rd grades.

NCT ID: NCT06441968 Not yet recruiting - COVID-19 Clinical Trials

Safety and Immunogenicity Trial of MPV/S-2P SARS-CoV-2 Vaccine in Adults

Start date: June 18, 2024
Phase: Phase 1
Study type: Interventional

A clinical trial to evaluate the safety, reactogenicity, and immunogenicity of MPV/S-2P administered intranasally to adults who have previously received a primary series and at least one booster with an authorized or licensed mRNA SARS-CoV-2 parenteral vaccine. The primary objective is to evaluate the safety and reactogenicity of a single dose of MPV/S-2P in previously vaccinated healthy adults.